SK Biopharm announced on September 14 that it has received the highest rating of 'AAA' from the Morgan Stanley Capital International (MSCI) ESG assessment for three consecutive years. It is the first domestic pharmaceutical company to achieve this rating for three years in a row, and currently, SK Biopharm is the only company to hold an AAA rating.
The MSCI ESG assessment is a leading evaluation system that compares and assesses companies' capabilities in managing key environmental, social, and governance risks and opportunities against their global peers. The company stated, "Despite recent changes in evaluation methodology that have made the criteria for transparency and evidence in ESG activities stricter, SK Biopharm has maintained the highest rating."
In this assessment, MSCI highlighted SK Biopharm's strengths in areas such as Corporate Behavior, Human Capital Development, and Product Safety & Quality, all rated at a global top level. In the Corporate Behavior category, the company's compliance system and transparency in accounting and taxation were noted, while in Human Capital Development, its member capability development programs and initiatives to foster a 'great place to work' culture received high marks.
In the Product Safety and Quality sector, the company was recognized for effectively managing risks based on a systematic quality management system and global certification standards.
SK Biopharm supports a virtuous cycle where new drug development and business growth lead to the creation of social value through its ESG management. The innovative drug cenobamate has expanded treatment options for epilepsy patients worldwide, with over 300,000 cumulative prescriptions globally.
Last year, SK Biopharm generated social value amounting to 498.7 billion won, with 452.4 billion won attributed to improvements in quality of life through its products and services.
Lee Dong-hoon, CEO of SK Biopharm, stated, "Our efforts in maintaining transparent governance centered on the board, responsible management, enhancing talent competitiveness, fostering a great workplace culture, and ensuring quality and safety management have been recognized."
Meanwhile, SK Biopharm's epilepsy drug candidate, opacalim (BHV-7000), recently received a partial clinical hold from the U.S. Food and Drug Administration (FDA). The company expects to submit additional non-clinical data to the FDA by the end of this month and anticipates that the hold will be lifted between October and November.
Opacalim is SK Biopharm's second global drug candidate following cenobamate. The company has entered into a global exclusive licensing agreement with Biohaven worth up to $795 million (approximately 1.1 trillion won).
The MSCI ESG assessment is a leading evaluation system that compares and assesses companies' capabilities in managing key environmental, social, and governance risks and opportunities against their global peers. The company stated, "Despite recent changes in evaluation methodology that have made the criteria for transparency and evidence in ESG activities stricter, SK Biopharm has maintained the highest rating."
In this assessment, MSCI highlighted SK Biopharm's strengths in areas such as Corporate Behavior, Human Capital Development, and Product Safety & Quality, all rated at a global top level. In the Corporate Behavior category, the company's compliance system and transparency in accounting and taxation were noted, while in Human Capital Development, its member capability development programs and initiatives to foster a 'great place to work' culture received high marks.
In the Product Safety and Quality sector, the company was recognized for effectively managing risks based on a systematic quality management system and global certification standards.
SK Biopharm supports a virtuous cycle where new drug development and business growth lead to the creation of social value through its ESG management. The innovative drug cenobamate has expanded treatment options for epilepsy patients worldwide, with over 300,000 cumulative prescriptions globally.
Last year, SK Biopharm generated social value amounting to 498.7 billion won, with 452.4 billion won attributed to improvements in quality of life through its products and services.
Lee Dong-hoon, CEO of SK Biopharm, stated, "Our efforts in maintaining transparent governance centered on the board, responsible management, enhancing talent competitiveness, fostering a great workplace culture, and ensuring quality and safety management have been recognized."
Meanwhile, SK Biopharm's epilepsy drug candidate, opacalim (BHV-7000), recently received a partial clinical hold from the U.S. Food and Drug Administration (FDA). The company expects to submit additional non-clinical data to the FDA by the end of this month and anticipates that the hold will be lifted between October and November.
Opacalim is SK Biopharm's second global drug candidate following cenobamate. The company has entered into a global exclusive licensing agreement with Biohaven worth up to $795 million (approximately 1.1 trillion won).
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.